Are Mesoblast and Acrux Limited too cheap to ignore?

Touching 52-weeks lows Mesoblast is rapidly approaching the time to deliver.

| More on:
a woman

You鈥檙e reading a free article with opinions that may differ from The Motley Fool鈥檚 Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are few better stocks on the ASX to buy for potential than Mesoblast limited (ASX: MSB). It has been touching 52-week lows in the last week as investor impatience over a business long on promise, but short on delivery starts to bite. The potential remains evident but so do the fundamentals of negative earnings per share and cashflows, with little likelihood of that changing over the next year.

However, Mesoblast remains a high-risk, high-reward proposition for those prepared to back its regenerative stem cell biotechnology. It鈥檚 in the process of developing a range of therapies for common diseases and medical complaints, the science being to develop stem cells that regenerate ageing or diseased body parts such as cartilage, bone and muscle.

A $170 million global capital raising in 2013 gives the company over $240 million in cash to fund ongoing research and development for the next few years and it now has late stage clinical trials in process across all four of its key focus areas in developing drugs for commercial sale. If able to rollout one or more of these products in the next few years, then multi-billion dollar revenues on high margins could be expected to equal an explosive share price.

Selling for $4.38 today Mesoblast is offering a 33% discount to its November valuation even though the company has announced it continues to make steady progress and remains highly confident of success. On May 29 it announced it鈥檚 bringing forward plans for its commercial manufacturing operations in Singapore, as it prepares for anticipated product launches in the United States and other major markets. It looks a speculative buy at today’s prices.

Other biotech businesses with big potential include Sirtex Limited (ASX: SIR) which is already growing sales of its innovative liver cancer treatment with potential for expansion if other clinical trials prove positive. While ADEMEDUS FPO (ASX: AHZ) recently completed an oversubscribed share placement to indicate investors still like its potential over short, medium, and long-term horizons. Selling for $0.81聽Acrux Limited聽(ASX: ACR) is a company under heavy selling pressure, but offers a yield of 10.8% based on 2014’s projected payout and a price-earnings of just over 4. Best of all is that any potential capital gains realised by investors on the sale of Acrux shares will not be included in their assessable income for that year. This is because Acrux has concessionary tax status as a Pooled Development Fund.

Smaller biotech stocks remain risky propositions, but there’s another company giving investors…

Motley Fool contributor Tom Richardson owns shares in Sirtex, Acrux and Admedus.聽You can find him on Twitter @tommyr345

More on 鈴革笍 Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
鈴革笍 Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
鈴革笍 Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more

asx share price competitions represented by businessmen arm wrestling
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more

asx investor daydreaming about US shares
鈴革笍 How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more

person reading news on mobile phone
鈴革笍 Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more